Drug Development Pipeline
BI 1265162 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
A phase 2 study to test the safety and effectiveness of BI 1265162 was completed. No further development in CF is planned.
This program was sponsored by Boehringer Ingelheim. It was conducted within the CFF's Therapeutics Development Network.
Recent BI 1265162 Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More